Nuvation Bio Stock Soars 39% on Q3 Results and Global IBTROZI Approvals

Introduction

Nuvation Bio Inc (NYSE: NUVB) is a publicly traded oncology company founded in 2018 by David Hung, M.D. The firm develops and commercializes cancer therapies that target drug-resistant or difficult-to-treat tumors. Nuvation Bio’s headquarters are in New York, with additional offices in San Francisco, Boston, and Shanghai.

Corporate Structure

According to LinkedIn data, Nuvation Bio employs between 51 and 200 people. Approximately 70–80 percent of its staff hold M.D. or Ph.D. degrees and have experience in drug discovery, clinical development, and commercialization. Nuvation Bio has registered 16,227,731 shares under its 2021 Equity Incentive Plan and 4,056,932 shares under its 2021 Employee Stock Purchase Plan (S-8 filing, November 3, 2025).

Oncology by Angiola Harry

Recent Developments and News

• On November 17, 2025, Nuvation Bio filed a Form 8-K (Items 7.01, 8.01, 9.01) with the SEC, signaling material corporate events.
• The company reported its third-quarter 2025 financial results and hosted a conference call on November 19, 2025 (LinkedIn).
• Taletrectinib (IBTROZI), a next-generation ROS1 inhibitor, received U.S. FDA approval in June 2025, along with Japanese MHLW approval and Chinese NMPA approval. Enrollment is under way in the TRUST-IV study for early-stage ROS1+ non-small cell lung cancer.
• Safusidenib, an mIDH1 inhibitor for diffuse IDH1-mutant glioma, is moving into a pivotal trial following a protocol amendment to include grade 2 high-risk patients.
• In March 2024, Nuvation Bio dosed the first patient in its Phase 1/2 dose-escalation study of NUV-1511, a small-molecule drug-drug conjugate for advanced solid tumors.
• NUV-868, a BD2-selective BET inhibitor, has completed Phase 1 monotherapy and Phase 1b combination studies; additional combination studies are under evaluation.

Financial and Strategic Analysis

As of the third quarter ended September 30, 2025 (Form 10-Q filed November 3, 2025):

Metric	Value
Trailing-12-month revenue	$26.75 million
Net loss (TTM)	–$217.48 million
Total cash (MRQ)	$549.04 million
Total debt/equity (MRQ)	17.66 percent
Shares outstanding	343 million (approx.)

On November 19, 2025, the stock closed at $6.6834, up 39.24 percent on volume of 7,887,763 shares, resulting in a market capitalization of approximately $2.29 billion. Management has indicated a cash runway of two to three years at a historical burn rate of $40–50 million per quarter. The company's strategy focuses on advancing its pipeline through pivotal trials, expanding commercialization of IBTROZI, and leveraging its drug-drug conjugate platform to develop new cancer therapies.

Market Position and Industry Context

Non-small cell lung cancer accounts for more than one million diagnoses annually worldwide, with an estimated 2 percent harboring ROS1 rearrangements. Brain metastases occur in approximately 35 percent of newly diagnosed metastatic ROS1+ NSCLC patients and in 50 percent of previously treated cases. In diffuse IDH1-mutant glioma, safusidenib’s blood-brain barrier penetration addresses an unmet medical need. The oncology market includes competing ROS1 inhibitors, mIDH1 compounds, and antibody–drug conjugates; Nuvation Bio positions its small-molecule conjugates as a potentially selective approach in addressing these conditions.

tl;dr

On November 19, 2025, Nuvation Bio’s stock increased by 39.24 percent to $6.6834 following the release of third-quarter results. The company holds FDA, MHLW, and NMPA approval for taletrectinib and is enrolling in the TRUST-IV trial for ROS1+ NSCLC. Safusidenib is entering a pivotal trial for IDH1-mutant glioma, NUV-1511’s Phase 1/2 study is ongoing, and further evaluation of NUV-868 combinations is under way. Cash reserves of $549 million provide a runway into 2027 under current burn rates. Upcoming milestones include pivotal data for safusidenib and further commercialization of IBTROZI.